Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

by Rebecca S Kristeleit, Antoine Italiano, Petri Bono, Giuseppe Curigliano, Analia Azaro, Katriina J Peltola, Pasi Hakulinen, Chris Garratt, Tarja Ikonen, Mika V J Mustonen
Published 2020-12-01

An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.

by David J Pinato, Chara Stavraka, Michael J Flynn, Martin D Forster, Séan M O'Cathail, Michael J Seckl, Rebecca S Kristeleit, David Olmos, Samantha J Turnbull, Sarah P Blagden
Published 2014-01-01

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

by Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Published 2021-05-01